影响患者报告结果响应率的因素 炎症性肠道疾病的患者报告结果
Vivica Dharmadasa1,2,3, Lai Mei Yip Lundström4, Niki Khatibi2
1Department of Gastroenterology, Dermatovenerology and Rheumatology, Centre for Digestive Health, Karolinska University Hospital, Stockholm, Sweden.
Scandinavian journal of gastroenterology
|May 10, 2025
概括
对炎症性肠病 (IBD) 进行皮下生物治疗的患者完成的患者报告结果测量 (PROM) 较少,这表明监测减少. 这凸显了需要多种多样的PROM施用方法,以确保全面的患者护理.
科学领域:
- 胃肠病学和临床免疫学
- 患者报告的结果措施 (PROMs)
- 生活质量 (QoL) 研究
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),显著影响患者的生活质量 (QoL).
- 患者报告的结果测量 (PROM) 是评估慢性病患者福祉和健康状况的关键工具.
- 识别患有监测不足风险的患者子组对于有效的疾病管理至关重要.
研究的目的:
- 确定患有IBD的问卷监测中可能错过的患者子组.
- 评估IBD患者的生命质量 (QoL) 和随时间的响应变化.
- 为了比较皮下和静脉注射生物治疗的PROM完成率.
主要方法:
- 包括412名成年患者 (CD:70%,UC:30%) 从2018年8月至2020年1月接受皮下或静脉注射生物治疗.
- 使用了验证的问卷:简短的健康量表 (SHS) 和EuroQol5维指数 (EQ5D) 用于QOL评估.
- 基于治疗类型和疾病活性进行统计分析,以比较PROM完成频率,QoL得分和响应变异性.
主要成果:
- 接受皮下治疗的患者比静脉注射治疗的患者填写PROM问卷的频率明显低 (少6.5倍).
- 降低的 QoL 与静脉注射治疗 (2.0x) 和活跃疾病 (-4.0x) 相关.
- 在患有活跃疾病,贫血或高便calprotectin水平 (≥250 mg/kg) 的患者中观察到更大的反应变化.
结论:
- 皮下注射,通常与家庭治疗相关,导致PROM完成率显著降低,导致患者监测较少.
- 这些发现强调了提供多样化的问卷管理方法的重要性,以适应异构的患者群体.
- 调整PROM策略至关重要,特别是随着IBD管理中口服治疗的日益增长的趋势.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
241
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
241
Irritable Bowel Syndrome I: Introduction
207
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
207
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Inflammatory Bowel Disease I: Ulcerative Colitis
98
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
98
Chronic Bowel Disorders: Introduction
319
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
319
Inflammatory Bowel Disease II: Crohn's Disease
129
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
129


